A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.

Early diagnosis of severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD) improves health outcomes by providing a specific treatment before the onset of symptoms. A high-throughput nucleic acid-based method in newborn screening (NBS) has been shown to b...

Full description

Bibliographic Details
Main Authors: Rafael Tesorero, Joachim Janda, Friederike Hörster, Patrik Feyh, Ulrike Mütze, Jana Hauke, Kathrin Schwarz, Joachim B Kunz, Georg F Hoffmann, Jürgen G Okun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0283024
_version_ 1797843145355952128
author Rafael Tesorero
Joachim Janda
Friederike Hörster
Patrik Feyh
Ulrike Mütze
Jana Hauke
Kathrin Schwarz
Joachim B Kunz
Georg F Hoffmann
Jürgen G Okun
author_facet Rafael Tesorero
Joachim Janda
Friederike Hörster
Patrik Feyh
Ulrike Mütze
Jana Hauke
Kathrin Schwarz
Joachim B Kunz
Georg F Hoffmann
Jürgen G Okun
author_sort Rafael Tesorero
collection DOAJ
description Early diagnosis of severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD) improves health outcomes by providing a specific treatment before the onset of symptoms. A high-throughput nucleic acid-based method in newborn screening (NBS) has been shown to be fast and cost-effective in the early detection of these diseases. Screening for SCD has been included in Germany's NBS Program since Fall 2021 and typically requires high-throughput NBS laboratories to adopt analytical platforms that are demanding in terms of instrumentation and personnel. Thus, we developed a combined approach applying a multiplexed quantitative real-time PCR (qPCR) assay for simultaneous SCID, SMA, and 1st-tier SCD screening, followed by a tandem mass spectrometry (MS/MS) assay for 2nd-tier SCD screening. DNA is extracted from a 3.2-mm dried blood spot from which we simultaneously quantify T-cell receptor excision circles for SCID screening, identify the homozygous SMN1 exon 7 deletion for SMA screening, and determine the integrity of the DNA extraction through the quantification of a housekeeping gene. In our two-tier SCD screening strategy, our multiplex qPCR identifies samples carrying the HBB: c.20A>T allele that is coding for sickle cell hemoglobin (HbS). Subsequently, the 2nd tier MS/MS assay is used to distinguish heterozygous HbS/A carriers from samples of patients with homozygous or compound heterozygous SCD. Between July 2021 and March 2022, 96,015 samples were screened by applying the newly implemented assay. The screening revealed two positive SCID cases, while 14 newborns with SMA were detected. Concurrently, the qPCR assay registered HbS in 431 samples which were submitted to 2nd-tier SCD screening, resulting in 17 HbS/S, five HbS/C, and two HbS/β thalassemia patients. The results of our quadruplex qPCR assay demonstrate a cost-effective and fast approach for a combined screening of three diseases that benefit from nucleic-acid based methods in high-throughput NBS laboratories.
first_indexed 2024-04-09T17:00:04Z
format Article
id doaj.art-eb612cf0eb904372958467e9e9f8ca7d
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-09T17:00:04Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-eb612cf0eb904372958467e9e9f8ca7d2023-04-21T05:33:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01183e028302410.1371/journal.pone.0283024A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.Rafael TesoreroJoachim JandaFriederike HörsterPatrik FeyhUlrike MützeJana HaukeKathrin SchwarzJoachim B KunzGeorg F HoffmannJürgen G OkunEarly diagnosis of severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD) improves health outcomes by providing a specific treatment before the onset of symptoms. A high-throughput nucleic acid-based method in newborn screening (NBS) has been shown to be fast and cost-effective in the early detection of these diseases. Screening for SCD has been included in Germany's NBS Program since Fall 2021 and typically requires high-throughput NBS laboratories to adopt analytical platforms that are demanding in terms of instrumentation and personnel. Thus, we developed a combined approach applying a multiplexed quantitative real-time PCR (qPCR) assay for simultaneous SCID, SMA, and 1st-tier SCD screening, followed by a tandem mass spectrometry (MS/MS) assay for 2nd-tier SCD screening. DNA is extracted from a 3.2-mm dried blood spot from which we simultaneously quantify T-cell receptor excision circles for SCID screening, identify the homozygous SMN1 exon 7 deletion for SMA screening, and determine the integrity of the DNA extraction through the quantification of a housekeeping gene. In our two-tier SCD screening strategy, our multiplex qPCR identifies samples carrying the HBB: c.20A>T allele that is coding for sickle cell hemoglobin (HbS). Subsequently, the 2nd tier MS/MS assay is used to distinguish heterozygous HbS/A carriers from samples of patients with homozygous or compound heterozygous SCD. Between July 2021 and March 2022, 96,015 samples were screened by applying the newly implemented assay. The screening revealed two positive SCID cases, while 14 newborns with SMA were detected. Concurrently, the qPCR assay registered HbS in 431 samples which were submitted to 2nd-tier SCD screening, resulting in 17 HbS/S, five HbS/C, and two HbS/β thalassemia patients. The results of our quadruplex qPCR assay demonstrate a cost-effective and fast approach for a combined screening of three diseases that benefit from nucleic-acid based methods in high-throughput NBS laboratories.https://doi.org/10.1371/journal.pone.0283024
spellingShingle Rafael Tesorero
Joachim Janda
Friederike Hörster
Patrik Feyh
Ulrike Mütze
Jana Hauke
Kathrin Schwarz
Joachim B Kunz
Georg F Hoffmann
Jürgen G Okun
A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.
PLoS ONE
title A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.
title_full A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.
title_fullStr A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.
title_full_unstemmed A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.
title_short A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.
title_sort high throughput newborn screening approach for scid sma and scd combining multiplex qpcr and tandem mass spectrometry
url https://doi.org/10.1371/journal.pone.0283024
work_keys_str_mv AT rafaeltesorero ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT joachimjanda ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT friederikehorster ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT patrikfeyh ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT ulrikemutze ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT janahauke ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT kathrinschwarz ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT joachimbkunz ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT georgfhoffmann ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT jurgengokun ahighthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT rafaeltesorero highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT joachimjanda highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT friederikehorster highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT patrikfeyh highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT ulrikemutze highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT janahauke highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT kathrinschwarz highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT joachimbkunz highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT georgfhoffmann highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry
AT jurgengokun highthroughputnewbornscreeningapproachforscidsmaandscdcombiningmultiplexqpcrandtandemmassspectrometry